Omnicell, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.
Starts at revenue growth over the last three years, -2.9% a year (statements).
US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt or cash not on file: 0 to start with.
What today's price assumes
A market value of $1.7 B means free cash flow growing 2.6% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.
Revenue grew -2.9% a year over the last three years.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | -7.94% | -5.44% | -2.94% | -0.44% | 2.06% |
|---|---|---|---|---|---|
| 8.15% | -39% | -27% | -12% | +7% | +30% |
| 9.15% | -47% | -36% | -24% | -8% | +10% |
| 10.15% | -52% | -43% | -33% | -20% | -4% |
| 11.15% | -56% | -49% | -40% | -28% | -15% |
| 12.15% | -60% | -53% | -45% | -35% | -24% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of Omnicell, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Healthcare Information Services
Multiples of its companies with a market value at most 60 days old, times Omnicell, Inc.'s own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | Omnicell, Inc. | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| Price to sales | 1.2× / 1.9× / 6.8× | 1.4× | revenue $1.2 B | $1.4 B to $8.0 B | 14 |
| Price to book | 1.2× / 2.4× / 4.9× | 1.4× | book equity $1.2 B | $1.5 B to $6.0 B | 14 |
Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.
Against its own history
Omnicell, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
P/E
43.5×Now below its median of 84.5×, in the bottom quarter of its range; range 27.8× to 917.9× over 24 months.
Price to sales
1.4×Now below its median of 1.5×; range 1.1× to 8.0× over 28 months.
Price to book
1.4×Now below its median of 1.5×; range 1.0× to 7.4× over 28 months.
as of Oct 27, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 27, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $1.2 B | $2 M | $127 M | $40 M | $87 M | — | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $1.1 B | $13 M | $188 M | $36 M | $151 M | — | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $1.1 B | $-20 M | $181 M | $41 M | $140 M | — | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $1.3 B | $6 M | $78 M | $48 M | $30 M | — | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $1.1 B | $78 M | $232 M | $29 M | $203 M | — | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $892 M | $32 M | $186 M | $23 M | $163 M | — | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $1.7 B on Oct 27, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.